Avapritinib
Ayvakit
Sources
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9
Overall Response Rate (95% CI) 84% (69%, 93%) 89% (75%, 97%) ... PDGFRA exon 18 N = 43, PDGFRA D842V N = 38 ... Gastrointestinal Stromal Tumors Intracranial hemorrhage occurred in 3 of 267 patients (1.1%).
Ayvakit USPI section 1.1, 5.1 and 14.1, Table 10, NAVIGATOR (NCT02508532)
publication, as of 2026-11-07
https://pubmed.ncbi.nlm.nih.gov/34343033/
Median PFS was not statistically different between avapritinib and regorafenib (hazard ratio, 1.25; 95% CI, 0.99 to 1.57; 4.2 v 5.6 months; P = .055) ... Objective response rates were 17.1% and 7.2%
Kang YK et al. J Clin Oncol 2021;39:3128-3139, PMID 34343033, abstract
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT02508532
A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03465722
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07